Introduction: Triple negative breast cancer (TNBC) is an aggressive breast 
cancer subtype associated with an increased risk of recurrence and 
cancer-related death. Unlike hormone receptor-positive or HER2-positive breast 
cancers, there are limited targeted therapies available to treat TNBC and 
cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan 
(IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and 
selectively delivering SN-38, an active metabolite of irinotecan. Areas covered: 
This review covers the mechanism of action, safety and efficacy of sacituzumab 
govitecan in patients with previously treated, metastatic TNBC. Additionally, 
efficacy data in other epithelial malignancies is included based on a PubMed 
search for 'sacituzumab govitecan' and 'clinical trial'. Expert opinion: 
Sacituzumab govitecan has promising anti-cancer activity in patients with 
metastatic TNBC previously treated with at least two prior lines of systemic 
therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase 
III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable 
side effect profile, with the most common adverse events being nausea, 
neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends 
beyond TNBC with promising early efficacy data in many other epithelial cancers, 
including hormone receptor-positive breast cancer.